BioCryst aims to leverage its commercial success to accelerate a robust pipeline based on structure-guided drug design

blonca9
May 21, 2024
1 min read

CEO Jon Stonehouse describes how making it across the finish line with Orladeyo has put BioCryst in a position after may decades of drug development to ramp R&D while partnering larger indications.

Recent Posts

See All

RBC Global Healthcare Conference: Korro Bio entered the clinic with its RNA editing platform in January and will have multiple cohorts of data in AATD later this year

RBC Global Healthcare Conference: With a phase 3 for its lead program scheduled to read in Q3 and mid-stage data for another program coming up this quarter, aTyr Pharma has pivotal months ahead

RBC Global Healthcare Conference: Ocular Therapeutix's Chairman & CEO Pravin Dugel provides an update on the progress of the pivotal studies for AXPAXLI in wet AMD

BioCryst aims to leverage its commercial success to accelerate a robust pipeline based on structure-guided drug design

Recent Posts

Join the BiotechTV mailing list

Follow BiotechTV

Sponsors

Sponsor Spotlight